5442 related articles for article (PubMed ID: 3263200)
41. Liposomes as vehicles for vaccines.
Alving CR; Banerji B; Shiba T; Kotani S; Clements JD; Richards RL
Prog Clin Biol Res; 1980; 47():339-55. PubMed ID: 7208512
[TBL] [Abstract][Full Text] [Related]
42. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
43. Liposomes as a tool to study the role of membrane presentation in the immunogenicity of a MuLV-related tumor antigen.
Gerlier D; Bakouche O; Dore JF
J Immunol; 1983 Jul; 131(1):485-90. PubMed ID: 6190925
[No Abstract] [Full Text] [Related]
44. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
[TBL] [Abstract][Full Text] [Related]
45. Immunoadjuvant action of liposomes: comparison with other adjuvants.
Gregoriadis G; Panagiotidi C
Immunol Lett; 1989 Feb; 20(3):237-40. PubMed ID: 2714847
[TBL] [Abstract][Full Text] [Related]
46. Targeting of tumor-associated antigens (TAA) in experimental immunotherapy.
Ravikumar TS; Galbo L; Marini C; Kaplan P; Valmont I; Cunningham JN
J Surg Res; 1986 Jun; 40(6):574-9. PubMed ID: 3747491
[TBL] [Abstract][Full Text] [Related]
47. Carrier and adjuvant properties of liposome-borne tumor-specific antigens.
LeGrue SJ
Cancer Immunol Immunother; 1984; 17(2):135-41. PubMed ID: 6565518
[TBL] [Abstract][Full Text] [Related]
48. Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy.
Adamina M; Schumacher R; Zajac P; Weber WP; Rosenthal R; Groeper C; Feder C; Zurbriggen R; Amacker M; Spagnoli GC; Oertli D; Heberer M
J Liposome Res; 2006; 16(3):195-204. PubMed ID: 16952874
[TBL] [Abstract][Full Text] [Related]
49. Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice.
Bergers JJ; Den Otter W; Dullens HF; De Groot JW; Steerenberg PA; Mimpen MW; Crommelin DJ
Cancer Immunol Immunother; 1993 Sep; 37(4):271-9. PubMed ID: 8348566
[TBL] [Abstract][Full Text] [Related]
50. Immunotoxicological characteristics of preparations based on carcinoembryonic antigen and mucin containing CA 125 antigen.
Sitdikova SM; Amandzholov BS; Sel'chuk VY; Kormosh NG; Laktionov KP; Lebedin YS; Chukanov SV; Toptygin AY; Manzyuk LV; Donenko FV
Bull Exp Biol Med; 2000 Apr; 129(4):389-91. PubMed ID: 10977930
[TBL] [Abstract][Full Text] [Related]
51. Immunological targets for cancer therapy: new recognition.
Shurin MR
Immunotargets Ther; 2018; 7():83-85. PubMed ID: 30538966
[No Abstract] [Full Text] [Related]
52. Effects of suramin on polyamine metabolism in B16 murine melanoma cells.
Gritli-Linde A; Björkman U; Delle U; Frostesjö L; Hultborn R; Hultén K; Johansson BR; Nannmark U; Linde A
Anticancer Res; 1998; 18(2A):855-62. PubMed ID: 9615732
[TBL] [Abstract][Full Text] [Related]
53. Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer.
Hirabayashi K; Okada E
Cancer; 1993 May; 71(9):2769-75. PubMed ID: 7682148
[TBL] [Abstract][Full Text] [Related]
54. Lectins as probes for identification of tumor-associated antigens on urothelial and colonic carcinoma cell lines.
Paulie S; Hansson Y; Lundblad ML; Perlmann P
Int J Cancer; 1983 Mar; 31(3):297-303. PubMed ID: 6826254
[TBL] [Abstract][Full Text] [Related]
55. In vivo binding of the radioiodinated peptide YIGSR on B16 melanoma cells.
Kouzi-Koliakos K; Koliakos G; Trontzos C; Papageorgiou A; Iliadis S; Triantos A; Dimitriadou A; Kanellaki M
Invasion Metastasis; 1996; 16(6):322-9. PubMed ID: 9371232
[TBL] [Abstract][Full Text] [Related]
56. Efficient spontaneous fusion between some co-cultured cells, especially murine melanoma cells.
Wakeling WF; Greetham J; Bennett DC
Cell Biol Int; 1994 Mar; 18(3):207-10. PubMed ID: 8019495
[No Abstract] [Full Text] [Related]
57. Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa.
Pang G; Buret A; Batey RT; Chen QY; Couch L; Cripps A; Clancy R
Immunology; 1993 Jul; 79(3):498-505. PubMed ID: 7691728
[TBL] [Abstract][Full Text] [Related]
58. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
Su TL; Chou TC; Kim JY; Huang JT; Ciszewska G; Ren WY; Otter GM; Sirotnak FM; Watanabe KA
J Med Chem; 1995 Aug; 38(17):3226-35. PubMed ID: 7650675
[TBL] [Abstract][Full Text] [Related]
59. Intraocular silicone prosthesis implantation in eyes of dogs and a cat with intraocular neoplasia: nine cases (1983-1994).
McLaughlin SA; Ramsey DT; Lindley DM; Gilger BC; Gerding PA; Whitley RD
J Am Vet Med Assoc; 1995 Dec; 207(11):1441-3. PubMed ID: 7493872
[TBL] [Abstract][Full Text] [Related]
60. Ia-like antigen expression on biologically different human melanoma cell lines.
Reynier M; Lebec S; Rohner C; Kalil J; Aubert C
Eur J Cancer Clin Oncol; 1984 May; 20(5):659-65. PubMed ID: 6376131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
